396 – Breast cancer screening: understanding risk, deciding when to start, and more

Key Takeaway

Most women aren't screening for breast cancer optimally—not because they skip screening entirely, but because they're not using the right strategy for their risk. The solution starts with a formal risk assessment by age 25, annual mammography beginning at 40 (not biennial), and supplemental MRI for high-risk women or those with dense breasts. Despite guidelines recommending MRI for 9% of women, only 0.4% actually get it—a massive execution failure that costs lives.

Episode Overview

Dr. Peter Attia provides a comprehensive guide to breast cancer screening, explaining why standard guidelines often fall short and how women can personalize their approach. He breaks down risk factors, imaging modalities (mammography, MRI, ultrasound), and screening frequency, emphasizing that individual optimization—not population-level efficiency—should drive decisions. The episode serves as a practical framework for giving yourself the best chance of not dying from breast cancer.

Full Transcript

Transcript of 396 – Breast cancer screening: understanding risk, deciding when to start, and more from The Peter Attia Drive Podcast. Auto-generated from episode audio; may contain minor errors.

Hey everyone, welcome to the Drive podcast. I'm your host Peter Ailla. Hey everyone, welcome to the Drive podcast. I'm your host Peter Aia. This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members.

And in return, we offer exclusive member onlyly content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. If you want to learn more about the benefits of our premium membership, head over to peterati.com/subscribe. Welcome to a new episode of The Drive. Today we're diving into breast cancer screening, why women are still dying from breast cancer despite effective screening tools, where current screening strategies fall short, and how to think about personalizing your own screening.

This episode is really about one central question. How do you give yourself the best possible chance of not dying from breast cancer? As we consider this to be a really important public service announcement, the full episode and the detailed show notes for this discussion will be available to everyone regardless of whether or not you're a premium subscriber. So without further delay, please enjoy this episode of The Drive. Most of us have heard that terrible statistic. About 1 in 8 women will develop invasive breast cancer over the course of their lifetime.

In the United States, roughly 42,000 women die every year from this disease. That makes it one of the leading causes of cancer death behind only lung, colarctal, and pancreatic. And yet, despite how common and consequential this disease is, many women have questions about screening, including when it should start, how often to do it, and what factors actually matter. Even women who have looked at the guidelines often come away more confused than before because the guidance differs between organizations, and it's also shifted over time. And that confusion has real consequences because breast cancer screening works.

Cancers found through screening are more likely to be caught early before they've spread when treatment is easier and outcomes are better. And that stage shift, as it's called, matters enormously. When breast cancer is caught at stage 1, the 10-year survival is over 96%. 96%. 96%. By stage 4, 5-year survival is only around 30%. around 30%. around 30%. It's no surprise then that women who screen regularly are up to 40% less likely to die from the disease. Now, of course, screening is not without trade-offs. For example, overdiagnosis of lesions that would never progress to cancer can increase healthcare burden with no real benefit and remains an area of ongoing uncertainty.

We'll get into these considerations later, but they do not negate the core point. Screening is one of the most effective tools we have for reducing breast cancer mortality. And if you're optimizing for your individual risk of dying from breast cancer, not population efficiency, not total societal cost, but your own outcome, the default should be to heir on the side of more effective screening and certainly not less. Which raises the obvious question. If screening works so well, why are so many women still dying from breast cancer every year?

every year? every year? Part of the answer is biology. Some breast cancers are simply more aggressive than others. They grow quickly. They spread early and can be difficult to intercept even with a very good screening system. Some back of the napkin math suggests that somewhere around 7 to 10% of cases are the ones we are unlikely to catch even with perfect screening. But those biologically aggressive cases are not the only reason this disease is still taking so many lives. A major and much more solvable part of the problem is far more mundane.

We are still under screening. And I don't just mean that some women never get a mammog though that is certainly part of it. Even among women who have been screened before, screening may be inconsistent. Roughly a third of women over 40 have not had a mammogram in the past 2 years. And even among women aged 50 to 74 where the evidence is most universally agreed upon about 20% are not up to date. Under screening has two layers. The first is pretty basic. Most women are not even getting routine mimography at the right time.

But the second is more nuanced. Some women are getting screened but not with the right strategy for their risk profile. This is one statistic that I think captures this perfectly. According to the criteria laid out by major screening guidelines, at least 9% of women meet the threshold for breast MRI as part of their screening protocol. And yet the actual utilization rate is just 0.4%. 4%. It's not that MRI is unproven or controversial for these women. This is a pure execution failure. We already know who these high-risisk women are and we already have a tool that materially improves detection.

We're simply not connecting the two. So, what I want to do today is not simply tell you to get screened. You already know that. I want to give you a practical framework for smarter screening. One that starts with understanding your actual risk, and helps you make informed decisions about when to start, how often to screen, and what imaging to use. Population guidelines form a great starting point, but they're not the finish line. But to get there, we need to start with the guidelines themselves. What do the major organizations actually recommend, and how should we talk about personalizing them?

them? them? If you're confused about breast cancer screening, you're not alone. A recent survey found that roughly 50% of women aren't sure when to start mimography. And frankly, that confusion is understandable. The guidance has shifted multiple times over the past two decades, most recently in 2024. There are several organizations that publish screening recommendations, and they do not all agree. Rather than walking through all of them individually, let me first give you the composite picture of the most rigorous guidelines. We'll include a full comparison table in the show notes.

Here's the big picture. Every woman should have a formal risk assessment by about the age of 25. If you are average risk, annual mimography should begin at 40. If you are high- risk, and I'll define that in a minute, you may need an MRI and eventually mimography much earlier, and screening should continue for as long as you would be willing to pursue treatment if cancer were found. That composite comes from groups like the American Cancer Society, the National Comprehensive Cancer Network, and the American College of Radiology.

The one notable outlier is the US Preventive Service Task Force or USPSF whose guidance tends to inform insurance coverage decisions. The USPSTF currently recommends mimography only every other year for average risk women aged 40 to 74 with no explicit recommendation for high-risisk women. Now, these are population level guidelines. They're created by looking at large studies and evaluating the optimal strategy for maximizing cancer detection while minimizing false positives across millions of women. And of course, they take into account the societal cost of screening. But when you move from populations to actual people, personalization matters.

personalization matters. personalization matters. When we think about how to personalize screening for any cancer, the first question we need to start with is what is my baseline risk? Then given that risk, how much false positive burden am I willing to tolerate in exchange for potentially earlier detection? And third, which screening plan, both modality and frequency best match both of these objectives? This is not about trying to outsmart the guidelines. It's about deciding whether the default plan actually fits you. For some women, it will, but for others, it will fall short.

The aim is not to get as much imaging as possible. It's to land on a strategy most likely to help someone with your particular risk profile. So, let's start with the first question. What actually determines your baseline risk? While most people immediately think of BA level risk when they think about breast cancer, most women who develop breast cancer do not have one dramatic obvious risk factor. It is far more common to have several smaller risk factors that together add up to a higher risk. So we are not just looking for the rare woman with the obvious red flag.

We want to identify the women whose overall risk is meaningfully above average. However, risk assessment is only useful if it happens early enough to change the plan. You do not want to find out at age 42 that you should have been the patient who started MRI years earlier. That is why some groups recommend formal risk assessment by age 25. Not because everyone needs imaging at 25, but because by then you want to know whether or not you are truly average risk or not. I think this is exactly right.

A risk assessment should be done in your mid20s. So what are the risk factors we need to consider? The most basic are the ones we don't usually think of as risk factors. Sex and age. Breast cancer is overwhelmingly more common in women. One versus 8 versus 1 in about 750 for men. So keep in mind men can develop this as well. Then there's age, which is one of the strongest breast cancer risk factors overall. The median age of diagnosis is around 62 and the vast majority of breast cancers are diagnosed after age 40.

While age alone is an imperfect guide, it is important to keep in mind that risk accumulates over time. But once you get past these two obvious risk factors, the most obvious high impact category is genetics. Mutations in genes like Bracka 1 and BA 2 are the most recognized inherited breast cancer risk factors and for good reason. They can substantially increase risk and often shift that risk earlier in life. But these mutations are actually much rarer than people tend to think. In the general population, only about 1 in400 people carry a pathogenic mutation in Bracka 1 or Bracka 2.

Though prevalence is higher in some groups, including people of Ashkanazi Jewish ancestry. There are also other important genes, but the broader point is that inherited mutations matter a great deal for screening, even if they account for a minority of breast cancer cases. And genetics ties directly into the next factor, family history. I separate these because family histories capture more than just the known single gene mutations. Yes, family history is a proxy for high impact mutations like the Bracka mutations, but it also reflects the cumulative effect of lower penetrant genetic varants, shared environmental exposures, and other inherited factors that no single genetic test currently covers.

covers. covers. Having multiple first or second degree relatives, parents, siblings, grandparents, aunts with breast cancer can substantially increase your risk. But keep in mind that lack of family history does not automatically equate to low risk. Some families are small. Some relatives may have died young of other causes. And importantly, some mutations that increase breast cancer risk can show up in the family as other cancers like prostate or pancreatic cancer rather than an obvious pattern of breast cancer. So, family history matters, but it should be interpreted thoughtfully.

and the absence of a family history of breast cancer does not guarantee that you are of average risk. In addition, ancestry related differences can influence both risk and tumor biology. In the US, for example, black women are more likely to be diagnosed younger and with more aggressive subtypes, which has implications for how early and how aggressively screening should be considered. considered. considered. Another important category is prior chest radiation. The classic example is radiation treatment for Hodkdins lymphoma in adolescence or early adulthood. Cumulative highdose exposure, particularly around the time when breast tissue is still developing, carries the greatest risk.

Now, to be clear, this does not mean you should avoid a diagnostic X-ray if your doctor recommends one. A single chest X-ray or CT delivers a tiny fraction of the dose used in cancer treatments. and the evidence that the occasional routine chest imaging study meaningfully increases breast cancer risk is very weak at best. Then there's breast density which is important for two separate reasons. First, dense breasts are associated with a somewhat higher baseline risk of breast cancer. But just as importantly, dense tissue makes mammogs harder to interpret because both dense tissue and tumors appear white on the image.

So density is not just a biological risk factor. It is also one of the main reasons our most common screening test becomes less effective. And this is where things get a little tricky. You usually cannot actually know your breast density until you've had an imaging study, which for most otherwise average risk women does not happen until screening begins at around age 40. This creates a bit of a catch 22. Density matters for screening decisions, but you often do not learn until it's potentially too late. There's a partial workaround, though.

Breast density is fairly heritable, roughly 60 to 70%. So, if your mother or grandmother was told she had dense breasts, that's worth knowing. It is just not something most women tend to think about. Density matters enough that the FDA now requires imaging centers to notify women of it. that is typically reported with the BRADS density category. A and B are considered nondense while C and D are considered dense. While density declines with age, about 50% of screening age women have dense breast tissue. Then there are the reproductive and hormonal factors which tend to be more cumulative in nature.

In general, the factors that point toward higher risk include earlier onset of menration, later menopause, never having had a full-term pregnancy, or having a first pregnancy after age 40 and not breastfeeding. Individually, none of these risk factors typically change the screening plan on its own, but they do contribute slightly to overall risk, especially when several are present together. The same is true, of course, of modifiable risk factors such as alcohol use, obesity, poor metabolic health, and physical inactivity. You don't need to change your screening protocol based on these alone, but they can shift risk and are factors you should actually do something about.

So, the big picture here is that risk is usually not one thing. It is the sum of multiple inputs, some large, some small, that together determine whether someone is truly average risk, somewhat above or below average, or clearly high risk. And because no one is going to accurately estimate all of that in their head, this is where formal tools can help. Calculators like Tyra Cusk combine family history, personal risk factors, and breast density to estimate 10-year and lifetime risk. These models are not perfect, but they are much better than guessing, and they help identify women whose risk is high enough to justify earlier or more intensive screening.

Most screening guidelines classify lifetime risk above 20% as high risk, though factors such as ancestry may shift that threshold. You can find these calculators online, but we're going to link to one in the show notes. And it's a good idea to complete one so you can get a more concrete understanding of where your risk falls. So, if you take anything away from this, know your risk and know it early enough that you still have time to act on it. But risk alone doesn't tell you what to do.

The next question is, given that risk, how aggressively do you want to be screening? Because every time you push screening towards higher sensitivity, that is finding more cancers, you also accept more downside, more false positives, and more follow-up testing. Not to mention the anxiety that can come with those. In a perfect world, screening would find every meaningful cancer early and spare everyone the downside of a false alarm. But in the real world, the balance is never that straightforward. In the US, about 10% of screening mimographies lead to a call back for additional testing, but only about 5% of those call backs end in a cancer diagnosis.

In other words, for every thousand women who undergo a screening mammog, about 100 will be called back because something looked abnormal, but about 95 of those hundred will not actually have cancer. And those numbers add up over time. More than half the women screened annually for 10 years will experience at least one false positive result. The most common harms from breast cancer screening are not major physical injuries from the test itself, but the anxiety and uncertainty that comes from a return visit for more imaging. imaging.

imaging. When a call back leads to an earlier cancer diagnosis, it's obviously worthwhile. But when most callbacks do not end in cancer, we need to think carefully about what screening strategy makes sense for each individual woman. So how should a woman think about that trade-off? The higher your baseline risk, the easier it is to justify accepting more false positives in exchange for finding more cancer earlier. If you're very high risk, say you carry a BA mutation or have a combination of factors that pushes your lifetime risk well above average, then a more aggressive strategy is easy to defend.

If you're truly average risk or even lower than average risk, the decision is based largely on preference. That does not necessarily mean less screening. It means being thoughtful about how much extra testing you're willing to accept for what may be smaller incremental benefits. And that's really the key here. More screening is not automatically better screening. The right question is not how much imaging can I get, but which strategy is most likely to help someone with my risk profile and am I comfortable with the trade-offs that come with that?

There's no universal answer to that question. Of course, it depends on the person. But once you know your baseline risk and you have a sense of your tolerance for false positives, you're ready for the next piece. Which screening tools actually exist? and how should you think about choosing between them? When we talk about breast cancer screening, it's often treated as if breast imaging were just one thing, but it's not. Breast imaging is a toolkit consisting of different varieties of mimography, MRI, and ultrasound. Some of these are best for routine screening, while others are more appropriate for followup on an abnormal finding or as a supplemental option in higher risk women.

We'll go through each of these here and I'll also place in the show notes a detailed comparison table. The foundation of screening of course is the mimography. Mammogs use lowd dose x-rays to look for breast cancer and for most average risk women they remain the starting point. One important strength of mimography is that it is particularly good at detecting calcifications such as those seen in ductal carcinoma incite or DCIS. DCIS is sometimes called stage zero breast cancer. The abnormal cells are still confined to the ducts rather than invading surrounding tissue if left untreated.

Estimates suggest that somewhere between 25 and 60% of DCIS cases may eventually become invasive cancer. A wide range that reflects how much we still don't know about the natural history of DCIS. But that uncertainty is precisely why early detection matters. and mimography is well suited for finding it. That said, not all mammograms are the same. In 2000, the FDA approved the first full field digital mimography system. And this is what most of us are thinking of when we hear mamogram. Standard digital mimography, sometimes called 2D mimography, is the technology that many research studies have historically used.

Most recently in 2011, digital breast tomosynthesis or DBT, commonly referred to as 3D mimography, was rolled out. DBT takes multiple images from different angles to create a more layered view of the breast. This results in better cancer detection with lower recall rates, particularly for women with dense breasts. Not every imaging center offers DBT, however, and sometimes there is still an added cost. However, this is the version of mimography I would prioritize. Again, especially for women with dense breasts. Mimography is the right foundation for virtually everyone.

But for women at higher risk, mimography alone may not be sensitive enough. This is where MRI comes in. While not a complete replacement for mimography, MRI is an important supplemental option. MRI uses magnetic fields and intravenous gatalinium based contrast to detect abnormal blood flow or tissue behavior that mimography can miss making it the most sensitive screening tool available. It is better for detecting very small invasive tumors and atypical cancers than any other imaging modality. But it's not perfect for everything. Mimography still does a better job with certain calcifications.

So MRI is generally used in addition to but not instead of mimography. The downsides are cost access and the use of IV contrast along with a higher call back burden because of the higher sensitivity. But if your goal is maximum cancer detection, MRI's sensitivity tends to outweigh these downsides. The full breast MRI is what most very high-risisk women are recommended for initial screening and may also be used for diagnostics after an abnormal test. More recently, many patients are opting for the abbreviated breast MRI, which in my mind is the most underutilized tool we have.

Based on current diagnostic accuracy data, the abbreviated protocol preserves nearly all of the sensitivity of the full exam, but takes only 10 to 15 minutes compared to 30 to 60 minutes for the full exam. That makes it cheaper, faster, and more scalable, while still providing dramatically better cancer detection than mimography alone. For women with extremely dense breasts, adding MRI after a negative mammogram cut the rate of interval cancers, meaning cancers found between screens, in half from 5 per thousand to 2.5 per thousand with mimography alone.

So for women who are high risk, have dense breasts, or simply want a more sensitive complement to mimography, MRI is the strongest option we have. In many screening settings, an abbreviated MRI is likely sufficient, while the full protocol may be more useful for diagnostic workup and select edge cases. If MRI is not feasible, the next best modality is contrast enhanced mimography or CM. CM is a newer modality introduced in 2011 that is basically mimography plus intravenous iodinebased contrast. It gives more functional information than a standard mammogram and can be a very reasonable alternative when MRI is unavailable or contraindicated.

This technology isn't yet widely available, but I do think it will become more popular in the future. Then there's ultrasound. Ultrasound uses sound waves rather than radiation or magnetic fields to create images of breast tissue. As with the other imaging modalities, ultrasound comes in different flavors. handheld, where a technician or radiologist moves the probe manually, and automated, where the machine acquires images more systematically. Both are more operator dependent than mimography or MRI, and both carry a higher false positive burden than you would see in those modalities.

Ultrasound can be useful as a supplemental imaging modality, but its value is highly dependent on two things. who performs the ultrasound and what baseline imaging you are adding it to. In one study, adding physicianperformed handheld ultrasound to a standard 2D mimography mimography mimography increased the rate of cancer detection by 4.2 per thousand women screened. A second study paired technician performed ultrasound with DBT, the more sensitive mammogram, and the detection boost was much smaller, only about 1.1 per thousand. So when the base imaging is better or the technician is less experienced, the incremental benefit of ultrasound shrinks.

That doesn't mean it's not worth doing, but it does mean its benefits are more variable than what we see when adding MRI to mimography. So, where does ultrasound best fit into practice? Because handheld ultrasounds allow for real-time visualization, they're an excellent option for getting more clarity on something suspicious seen on other imaging or guiding biopsies. And while ultrasound can boost cancer detection over mimography alone, it's not going to do it to the same extent seen with adding MRI. Ultimately, ultrasound is a viable tool, but for average risk women, it is not a substitute for mimography.

And for high-risisk women, it's not a substitute for MRI. So, how do we actually pull all of this together in a way that is useful? At a practical level, the hierarchy looks like this. The foundation for all women is mimography, ideally digital breast tomosynthesis or DBT. If your risk is elevated or if dense breast tissue is likely to reduce the sensitivity of mimography, MRI is the most effective supplemental tool. If MRI is not feasible due to cost access or contraindication, contrast enhanced mimography is the next best option.

Ultrasound can add incremental detection, but its benefit is more variable and highly dependent on operator skill and on, of course, baseline imaging that it's paired with. The key point is that these tools are not interchangeable. They have a clear hierarchy in terms of sensitivity and consistency. And your goal is to choose the combination that best matches your risk. But regardless of the screening tool you decide on, keep in mind that where you get screened matters. Not every imaging center offers every modality and not every center has the same level of experience with the tests it offers.

Simply having imaging done is not the same thing as having highquality imaging done. For mimography, positioning and complete tissue capture matter. MRI and CM are more standardized, but they still depend on good protocol execution, contrast timing, and experienced interpretation. For the reasons I discussed a moment ago, ultrasound is the most operator dependent modality. So, a routine mammog can usually be done well in many places, but the quality of imaging and interpretation still varies. High volume centers and dedicated breast imaging centers tend to have more experience, better protocols, and more consistent interpretation.

interpretation. interpretation. If you are pursuing more advanced imaging such as MRI or contrast enhanced mimography or even ultrasound in dense breast tissue, you should strongly consider going to a center that performs these studies frequently and has specialized expertise. The difference is not trivial and in some cases it can directly affect whether a cancer is detected or not. Bottom line here is that each imaging modality has strengths and weaknesses and which one or which option you choose is a personal choice based on your risk, your preferences and your access.

Once you think about imaging in that way, the next question becomes how often should you screen? As I mentioned previously, the US PSTF recommends bianial mimography for average risk women aged 40 to 74. Most other groups recommend annual mimography starting around the age of 40 or a hybrid approach with annual screening from 45 to 54 and bianial screening thereafter. Though I've never really understood that given that risk is always going up with age. It's worth acknowledging upfront that no randomized control trial has ever directly compared annual versus bianial screening with mortality as its primary endpoint.

Every interval recommendation we have is based on modeling studies and observational data. That does not mean we're flying blind, but it does mean we are working with a slightly different kind of evidence than we have for say the question of whether screening reduces mortality at all. The most important modeling data come from the cancer intervention and surveillance modeling network or CISNet, a consortium of independent modeling groups funded by the national cancer institute. CISnet has been commissioned three times to run simulations for the US PSTF and the task force has leaned heavily on these models to justify bianial amography recommendations.

Interestingly, other cancer and radiology groups have looked at the same CISNET data to conclude that annual screening is better. So, which is it? The answer depends on your question. If the question is how to maximize efficiency across an entire population, balancing cost, false positives, and resource utilization, bianial screening is a defensible answer. But if the question is what gives an individual woman the best chance of avoiding death from breast cancer, the answer is different. And that distinction is critical for everything that I'm about to say.

The argument for bianial mimography traces back to the original 2009 cysnet analysis which found that bianial screening retained about 81% of the mortality benefit of annual screening with roughly half as many false positives. This was done using data from filmbased mimography, the technology that came before digital mimography and certainly before DBT was introduced. The conclusion from this modeling study was not that biionial mimography was best for mortality, but that it offered the best tradeoff between benefit and resource use at a population level. In 2024, CISNet published its most comprehensive analysis using multiple models and imaging strategies, including both two-dimensional digital mimography and DBT.

A secondary analysis of those results showed in essence that annual screening is better for saving lives. When compared to no screening, annual screening of women aged 40 to 79 produced a 42% mortality reduction, while bianial screening produced only a 30% mortality reduction. In absolute numbers, this corresponded to 230 life years gained per thousand women for annual screening versus 165 for bianial. The cumulative number for false positives is higher for annual screening as we would expect given that we're performing twice as many tests. However, the rate of false positives and benign biopsies per exam is actually lowest with annual screening, likely because the radiologist has a more recent image to compare to, making it easier to distinguish cancerous changes from normal variation.

I think this is a very important statistic that gets overlooked. The bottom line is that the case for bianial screening rests on population level efficiency, not on maximizing the benefits for any individual woman. If the question is what gives you the best chance of not dying from breast cancer, CISNet's own data answers it clearly. Screen annually. annually. annually. The observational data tell a similar story. Among women aged 40 to 84 who developed breast cancer, those screening annually had far fewer interval cancers, 11% versus 38% for bianial screeners, and were more likely to have an early stage diagnosis, 76% stage 1 with annual screening versus 56% with bianial.

Taken together the modeling and observational data, the conclusion is straightforward. If your goal is to maximize your chances of avoiding death from breast cancer as an individual, annual mimography is the better strategy. better strategy. better strategy. But all of these studies have focused entirely on mimography. What about when to add in other imaging modalities such as MRI? The most common approach in clinical practice is to alternate the two tests every 6 months. say mimography in January, MRI in July, rather than stacking them at the same time.

The logic is kind of intuitive. By spacing them out, you're effectively creating a six-month screening interval instead of a 12-month one, which in theory gives the fastest growing cancers less time to develop between the screens. But the evidence here is thinner than you might expect, in large part because these studies are genuinely hard to do well. When two tests are given at two different times, it becomes very difficult to fairly credit a cancer detection to one test versus the other, which makes comparing the two scheduling approaches unreliable.

approaches unreliable. approaches unreliable. One small study found that the combined sensitivity of MRI plus mimography was higher than either test alone, while another found no significant difference between stacking and alternating. Neither is definitive. For ultrasound plus mimography, the timing question has essentially never been studied directly. All major ultrasound trials performed both tests simultaneously and annually. Any rationale for staggering ultrasound is purely extrapolated from the already limited MRI literature. The bottom line on multimodality scheduling is rather unsatisfying. We do not yet have compelling evidence to favor one schedule over another.

I might lean towards the alternating schedule for high-risisk women who are more likely to develop rapidly growing cancers, but until better prospective data exists, the scheduling decision is really more about logistics and personal preference. To summarize the practical takeaway here, all women should screen annually with mimography. If you are high- risk and you are getting multiple imaging modalities, alternating them every six months is reasonable, but the evidence is not strong enough to insist on that schedule. Right now, the bigger issue is not whether the tests are staggered.

It's whether both tests are getting done consistently each year. Okay. At this point, we know we should do a risk assessment in our mid20s and we know how often to screen and which imaging modalities make sense. The next question is when should we actually start screening? I saved this for last because this is the area where we have the least concrete data beyond the whole scheduling thing. The intuitive assumption is that if screening saves lives, then starting earlier should save more of them. But whether earlier screening actually helps depends on many factors.

And the answer is more nuanced than you might expect. First, the risk for developing breast cancer before age 40 is genuinely low. Only about 5% of breast cancer diagnoses occur in women under 40. The cumulative risk through age 90 is about 13%, which is where that familiar 1 in8 statistic comes from. But the cumulative risk through age 40 is less than 1%. Now the obvious next question, how do we know incidence is actually low if we're not routinely screening women under 40? Maybe we are just not finding cancers that are there.

But these data come from cancer registries which capture all diagnosed cancers including cancers found symptomatically and cancers caught in women who began screening earlier because of elevated risk. On top of that, the age incidence curves rise smoothly and continuously through the 30s and 40s. We've included a figure in the show notes so you can take a look at this for yourself, but there is no sharp spike at age 40, which is what you would expect to see if screening were suddenly uncovering a large hidden backlog of disease.

So, the low incidence under 40s appears to be real, not an artifact of under detection. But low risk does not mean no risk. So could there still be a case for screening before 40? This is where we run into the limits of evidence. We have no randomized trials and no mortality data on screening average risk women under 40. The best study we have looked at about 6 million mammogs from facilities across the US. About 12% of these mammogs were from women under 40. And the researchers compared cancer detection rates across age groups broken down by whether a woman had at least one risk factor defined as a personal history of breast cancer, a family history in a first-degree relative or dense breasts.

Among women aged 35 to 39 with at least one risk factor, the cancer detection rate was 2.1 per thousand women screened. For average risk women in the same group with no family history, no personal history, and non-dense breasts, the rate was just 0.59 per 1,000. This is about a 3 1/2 fold difference driven by risk factors, not age alone. And here is where the comparison gets especially interesting. For average risk women aged 40 to 44, the detection rate was only 0.71 per thousand. In other words, women in their late30s with risk factors were being diagnosed with cancer at roughly three times the rate of average risk women who were screening in their 40s.

Those risk factors are not just nudging the needle. They are effectively shifting a woman's screening profile forward by a decade. Once you get to women 45 and older, incidence rises enough that detection rates exceed what we would see in women under 40, regardless of risk. But below that threshold, risk factors may matter more than age. This brings us back to the point I've made throughout this discussion. Knowing your baseline risk is what makes the difference. The age 40 cutoff for screening makes sense on average, but for women with with one or more of these three risk factors we've just discussed, earlier screening may be the right call.

And the women who are diagnosed with breast cancer in their 20s and 30s are not a random cross-section of the population. They are disproportionately women who could have been identified as above average risk earlier on. On top of this, breast cancer doesn't look the same in younger women as it does in older women. Younger women are much more likely to develop aggressive subtypes. About 20% of breast cancer in women under 40 are the so-called triple negative, the most aggressive form compared with roughly 6 to 12% in women over 40.

And these tumors grow fast. Triple negative cancers can double in size in under four months, which means even annual screening may not catch them in time. On the other end of the spectrum, the slower growing cancers that screening is best at detecting, the ones with doubling times closer to a year, make up only about a third of cases in women under 40, compared to well over a half in older women. For high-risisk women, this biology has direct implications for which screening tool to use. Mimography alone may not be enough.

Consider how risk from a BA 1 mutation plays out over a lifetime. It's not spread evenly. It's heavily front-loaded. A woman in her late 20s carrying a BA 1 mutation has a breast cancer risk roughly 100 times that of a non-arrier. By her 30s, it's about 44 times. And by her 60s, it drops to about three times. In other words, these mutations don't just increase risk. They shift the entire risk curve earlier. earlier. earlier. And because the cancers that develop in these younger, high-risisk women tend to be fast growing and harder to see on mimography, MRI is the more appropriate screening tool for this group.

There is one more practical consideration worth mentioning. mentioning. mentioning. One of the three risk factors in the study I just discussed was breast density. And as I mentioned to you earlier, you cannot know your breast density without imaging, at least definitively. About half of women have dense breasts. And density is higher in younger women than older women. So there's a reasonable argument for getting a single baseline mamogram in your 30s, not primarily to find cancer, but to establish whether you have dense breasts. If you do, that changes your risk profile and may change your screening strategy.

To be clear, this is less about cancer detection and more about risk stratification. And while there is no direct evidence supporting this approach, it's something that I think is worth considering. So, when should you start screening? As with everything else we've talked about, it depends on your risk. If you are truly average risk, beginning annual mimography at 40 is well supported. Though you may want to consider getting a baseline mammogram in your 30s at a minimum to establish your breast density. If you are above average risk, there is a small amount of evidence that mimography in your 30s can be worthwhile.

And if you're clearly high risk, a known bracker, a strong family history, or prior chest radiation, the conversation is different entirely and more aggressive screening protocol should be started in your 20s or early 30s. Now, everything we have discussed so far is about routine screening, finding cancer before it causes symptoms. But there's one type of breast cancer that does not follow those rules. And I want to make sure we address it before we wrap up. Inflammatory breast cancer is a rare type of cancer, roughly 1 to 5% of all breast cancers.

But it is aggressive and it does not present the way most people expect breast cancer to present. There is often no discrete lump. Instead, what you may notice is rapid swelling or heaviness of the breast, redness or rash, warmth, or changes in skin texture or thickness. Because these symptoms can look like skin irritation or something else relatively benign, diagnosis is frequently delayed. And this is the key point. Normal screening mimography does not rule out inflammatory breast disease. These cancers may not be visible on mimography. So, a diagnostic workup is necessary.

This is an important reminder that screening tests are designed for women without symptoms. If you notice something new, a lump, skin changes, nipple discharge, pain that does not resolve, do not wait for your next scheduled screening. A recent normal screen does not guarantee everything is fine. Go and get evaluated in person by your doctor. And this applies to men, too. I have focused this discussion on women because the vast majority of breast cancers occur in women. But men do develop breast cancer. Because we do not routinely screen men, symptoms are typically the only path to diagnosis.

A new symptom in a man should not be dismissed. It should be evaluated just as it would be in a woman. All right. So, where does all of this leave us? We started this episode with a question. If screening works so well, why are 42,000 women still dying from breast cancer every year? Part of the answer is biology. Some cancers are aggressive enough that they will evade even the best screening. But the far larger part, and the one that we can actually do something about right now, is that we are not screening intelligently enough.

A quarter of eligible women are not up to date on basic mimography. The vast majority of women who qualify for MRI are not getting it. And most women have never had a formal risk assessment. The science here is not the bottleneck. The tools exist. The evidence is strong. What is missing is the bridge between what we know and what women are actually doing. And to be clear, this is not an individual failure. Access to MRI is limited in many areas. Insurance coverage is often tied to the USPSTF recommendations which do not fully address high-risisk populations.

Imaging quality varies across centers. All of these system level factors contribute to under screening and suboptimal screening. But there is still a great deal that is within your control. So if you take nothing else from this episode, let it be this. First, complete a risk assessment using a validated risk calculator like the one we'll link to in the show notes so you have a quantitative sense of your baseline risk. Second, find out your breast density from prior imaging or plan to establish it when you begin screening.

Third, choose a cancer screening strategy, both modality and frequency that matches your level of risk and your tolerance for false positives. and fourth, execute that plan consistently over time. None of these steps are complicated, but taken together, they are what separates passive screening from intentional personalized screening. With the current technology, we cannot reduce breast cancer deaths to zero. But far too many lives are still being lost because we are applying the right tools too late, too inconsistently, or to the wrong people. At least at the individual level, this problem is more solvable than most people realize.

If risk is assessed, the right screening strategy is chosen, and the screening is actually carried out. Thank you for listening to this week's episode of The Drive. Head over to peterati.com/shownotes peterati.com/shownotes peterati.com/shownotes if you want to dig deeper into this episode. You can also find me on YouTube, Instagram, and Twitter, all with the handle Peter MD. You can also leave us review on Apple Podcasts or whatever podcast player you use. This podcast is for generalformational purposes only and does not constitute the practice of medicine, nursing or other professional healthcare services, including the giving of medical advice.

No doctor patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their health care professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit peterati.comabout, where I keep an up-to-date and active list of all disclosures.